Drug Discovery

  • In this issue
    Recent advances in RNA biology have accelerated the progress of a new generation of molecular therapies based on RNA, with several agents now in advanced clinical trials. In our first Review, Kole and colleagues compare and contrast the mechanisms of action and effects of three
  • (Mis)treating the pharmacogenetic incidentalome
    Genome-wide screening is anticipated to accelerate the development of personalized medicine by identifying and exploiting new associations between genomic variants and drug responses. However, this goal could be undermined if care is not taken to minimize the impact of pharmacogenomic associations that turn out to
    Isaac S. Kohane
  • 2011 FDA drug approvals
    The US FDA approved 30 new therapeutics last year, including 11 first-in-class agents.
    Asher Mullard
  • News in brief
    Globalization of clinical trials plateaus?The off-shoring of clinical trials outside the United States and Europe may have hit a plateau.The lowdown: Over the past decade, drug sponsors have increasingly shifted clinical trial programmes from the United States and Europe to the rest
  • Deal watch: Abbott boosts investment in NRF2 activators for reducing oxidative stress
    In one of the largest preclinical-stage deals ever, Abbott has agreed to pay US$400 million upfront to Reata Pharmaceuticals as part of an agreement to jointly develop and commercialize a series of second-generation oral antioxidant inflammation modulators (AIMs) with potential applications in cardiovascular disease, neurodegenerative
    Sarah Crunkhorn
  • Trial watch: BTK inhibitor shows positive results in B cell malignancies
    Preliminary clinical trial data recently presented at the American Society of Hematology meeting showed that the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 was effective in treating in several types of B cell lymphoma. Furthermore, PCI-32765 is at the centre of a deal — worth up
    Charlotte Harrison
  • Patent watch
    Regeneron and Genentech's VEGF trap dispute settles... and continues Regeneron and Genentech have settled their patent dispute over Eylea (aflibercept) — a treatment for wet age-related macular degeneration — which was launched onto the US market in November 2011. But the biotech companies are still
    Charlotte Harrison
  • RuiPing Dong
    Late last year Merck & Co. announced plans to spend US$1.5 billion to bolster research and development (R&D) in China, one of the industry's largest investments in the country to date. The firm's initial plans include, by 2014, the construction of an Asian R&D headquarters in Beijing and a doubling of their Chinese research staff count to 600 employees. Overseeing the expansion is RuiPing Dong, head of emerging markets R&D. Prior to joining Merck in 2010, Dong headed up Bristol-Myers Squibb's R&D efforts in Asia-Pacific and the emerging markets, and supervised AstraZeneca's oncology programmes. Speaking with Asher Mullard, he explains the strategy behind the Chinese R&D expansion.
  • The neuropathic pain market
    This article discusses the drug pipeline for neuropathic pain, for which the market is forecast to grow by 50% by 2020.
    Sarah Nightingale
  • Ruxolitinib
    In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
    Ruben A. MesaUma YasothanPeter Kirkpatrick
  • Protein conformational diseases: Rescuing protein homeostasis
    The maintenance of protein homeostasis (proteostasis) is vital for cell function and involves a tightly regulated network of pathways controlling the synthesis, folding, transport and degradation of proteins. Loss of proteostatic control can lead to the accumulation and aggregation of misfolded proteins — features that
    Sarah Crunkhorn
  • Obesity and diabetes: An FGFR antibody with long-lasting effects
    Although preclinical studies suggest that fibroblast growth factor 21 (FGF21) might have disease-modifying properties in obesity and type 2 diabetes, recombinant FGF21 protein has poor pharmacokinetics, which precludes its clinical use. Now, writing in Science Translational Medicine, a group from Genentech describes the identification
    Charlotte Harrison
  • Drug delivery: Encapsulation improves therapeutic stem cell action
    The recurrence and mortality rate of patients with glioblastoma multiforme (GBM) is close to 100%. At present, therapy consists of surgical debulking of the tumour followed by radiation therapy and chemotherapy. Preclinical studies have shown that therapeutically engineered stem cells may be well suited to
    Monica Hoyos Flight
  • Medicinal Chemistry: Shades of chemical beauty
    The concept of drug-likeness — which is based on the observation that physicochemical properties of drugs, such as molecular mass and lipophilicity, tend to fall within a relatively narrow range of the possible values — is widely used to prioritize compounds in early-stage drug discovery.
    Peter Kirkpatrick
  • Anticancer drugs: Keeping one step ahead
    Inhibiting the oncogenic kinase BCR–ABL1, which causes chronic myeloid leukaemia (CML), is a paradigm for clinically successful targeted therapy. However, drug-resistant mutations frequently emerge during clinical treatment. A new study shows that attempting to inhibit drug-resistant BCR–ABL1 mutants can result in a counterproductive activation of
    Darren J. Burgess
  • Lung disease: Blocking TGFβ improves emphysema
    Signalling mediated by transforming growth factor-β (TGFβ) is dysregulated in lung disorders such as emphysema. This study showed that blockade of TGFβ improved disease symptoms in a mouse model of cigarette smoke-induced emphysema. Administration of a TGFβ-specific neutralizing antibody prevented alveolar cell death, and improved
    Charlotte Harrison
  • Drug safety: Predicting adverse drug reactions
    Cami et al. describe a computational network-based method for predicting adverse drug reactions (ADRs). They collected drug safety data from 2005 and used it to construct a network of known drug–ADR associations. This was used to train a logistic regression model to predict unknown
    Charlotte Harrison
  • Neurodegenerative disorders: A neuroprotective role for sirtuin 1
    Cellular metabolism has a key role in the pathogenesis of Huntington's disease (HD), which is caused by the accumulation of mutant huntingtin protein (HTT). These two studies show that sirtuin 1 (SIRT1), an NAD-dependent protein deacetylase involved in the control of cellular metabolism, has neuroprotective
    Charlotte Harrison
  • Targeting IAP proteins for therapeutic intervention in cancer
    Evasion of apoptosis is one of the crucial acquired capabilities used by cancer cells to fend off anticancer therapies. Inhibitor of apoptosis (IAP) proteins exert a range of biological activities that promote cancer cell survival and proliferation. X chromosome-linked IAP is a direct inhibitor of
    Simone FuldaDomagoj Vucic
  • RNA therapeutics: beyond RNA interference and antisense oligonucleotides
    Here, we discuss three RNA-based therapeutic technologies exploiting various oligonucleotides that bind to RNA by base pairing in a sequence-specific manner yet have different mechanisms of action and effects. RNA interference and antisense oligonucleotides downregulate gene expression by inducing enzyme-dependent degradation of targeted mRNA. Steric-blocking
    Ryszard KoleAdrian R. KrainerSidney Altman
  • Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
    Studies of psychiatric disorders have traditionally focused on emotional symptoms such as depression, anxiety and hallucinations. However, poorly controlled cognitive deficits are equally prominent and severely compromise quality of life, including social and professional integration. Consequently, intensive efforts are being made to characterize the cellular
    Mark J. MillanYves AgidMartin BrüneEdward T. BullmoreCameron S. CarterNicola S. ClaytonRichard ConnorSabrina DavisBill DeakinRobert J. DeRubeisBruno DuboisMark A. GeyerGuy M. GoodwinPhilip GorwoodThérèse M. JayMarian JoëlsIsabelle M. MansuyAndreas Meyer-LindenbergDeclan MurphyEdmund RollsBernd SaletuMichael SpeddingJohn SweeneyMiles WhittingtonLarry J. Young
  • The critical impact of time discounting on economic incentives to overcome the antibiotic market failure
    As summarized in a recent article (Antibacterial R&D incentives. Nature Rev. Drug Discov.10, 727–728 (2011)), numerous 'push' and 'pull' economic incentives have been proposed to rekindle the antibiotic pipeline. These have been the
    Brad SpellbergPriya SharmaJohn H. Rex
  • Quarter-century quest for malaria vaccine shows signs of success
    Nature Reviews Drug Discovery10, 887–888 (2011) The spelling of Stephen Hoffman's name has been corrected online, as has his affiliation.
    Alisa Opar
  • Designing antimicrobial peptides: form follows function
    Nature Reviews Drug Discovery11, 37–51 (2012) 10.1038/nrd3591The page numbers of reference 180 in this article are incorrect; these should be 10686–10689. This has been corrected in the online version of the article.
    Christopher D. FjellJan A. HissRobert E. W. HancockGisbert Schneider


Share

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

*